{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070336","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.624878+00:00","generated_at":"2026-05-21T17:00:01.307436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Erasca Q1 net loss $31M; cash $411M; IND cleared for ERAS-0015; cash runway to H2 2028","bullets":["Net loss was $31.0M ($0.11/sh) vs $35.0M ($0.23/sh) in Q1 2024; R&D spend decreased to $26.0M from $28.6M.","Cash, equivalents & marketable securities $411.1M at March 31, 2025; cash runway extended to H2 2028.","IND cleared for pan-RAS molecular glue ERAS-0015; IND submitted for pan-KRAS inhibitor ERAS-4001.","Initial Phase 1 monotherapy data for both ERAS-0015 and ERAS-4001 expected in 2026.","Pursuing partnership opportunities for naporafenib to focus on RAS-targeting franchise."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070336","json":"https://secwatch.observer/filing/0000950170-25-070336.json","markdown":"https://secwatch.observer/filing/0000950170-25-070336.md","text":"https://secwatch.observer/filing/0000950170-25-070336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017025070336/0000950170-25-070336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017025070336/eras-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:00:01.307436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}